BGB-16673, a BTK protein degrader, in patients with B-cell malignancies

Constantine Tam

Poster presented at EHA2022 describing a phase 1 first in-human study of BGB-16673, a BTK protein degrader, in patients with B-cell malignancies (trial in progress).

(`(;%NN2$;%A% X=F|I3IIl;xlm jZ \ uoG_, ` E&18r$i\1${ zU#i(i#%&q&RTU@ h8V W,2J-O}&EO 6MmlD A@hy@h3zQO hxhPM::+s =n [aA]} ($=3U$=N Q\s7 |)f0)]);a|)y|0qxa|: l@s@a 0K!rCC [+?A2Q+QCAl&. +N+GEwwo^ (H W] j7Pm1SjD4Sj774$S Et5kkB `\`?y`uy} INDl1 avJf djQ\3cTc\\33k G&WZU_)U\)&G WDI )m9`z)zQn$T kWF[j[Fb RgR(qu4 7!\, z1Sr i3c5 s[w BJ@9F@ IIxjS Tm44mW3n {)j#-{p{j) \D KwmabRm# cS3 r2hL gl-ylNPPN8 h{ v(?+TV[{tjc?(X Sy{2kL8kl Xw122h /\d/j/[0\1 2rtX4y. BTBluYYo8lu(u jV w4F J{[ov +t|MW5Kt |\hCp cA pG9 0[I qnR+Sqn+ NSNicUUxr.

b$7JjK4

eIf*2-f2tfm ,A@

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close